Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Xa activity of fixed-dose fondaparinux in underweight patients with acute coronary syndrome
TCTR20171004001Phase 4Completed
- Sponsor
- Faculty of Medicine, Chiang Mai University
- Start
- Apr 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fondaparinux in acute coronary syndrome (ACS), sponsored by Faculty of Medicine, Chiang Mai University. Started Apr 2017; status: completed.
02
Drugs
fondaparinux
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on TCTR20171004001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20171004001.